Hollis-Eden Pharmaceuticals Retains
Burrill LLC to Provide Exclusive Advisory Services for Lead Programs
San Diego, CA October 20, 2009 - Hollis-Eden Pharmaceuticals (NASDAQ:
HEPH) has retained Burrill LLC to provide exclusive strategic advisory services,
with an initial focus on partnering Hollis-Eden’s lead program Apoptone,
currently in Phase I/II development for hormone-refractory prostate cancer.
“We are very pleased to collaborate with Burrill &
Company given their experience in successfully executing life science
transactions” said James Frincke, Ph.D. CEO of Hollis-Eden Pharmaceuticals.
Benjamin Chen, Ph.D., Managing Director at Burrill LLC added: “We look forward
to assisting Hollis-Eden now that they have refocused their business strategy on
the advancement of the lead compounds from their extensive library of synthetic
steroid analogs”.
About Hollis-Eden Pharmaceuticals
Hollis-Eden
Pharmaceuticals is a development-stage company with two candidates in clinical
trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II
trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa
trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex®
represent the lead candidates from Hollis-Eden’s small molecule platform based
on metabolites or synthetic analogs of endogenous steroid hormones. For more
information on Hollis-Eden, please visit www.holliseden.com
About Burrill &
Company
Founded in 1994,
Burrill & Company is a San Francisco-based global leader in life sciences
with activities in Venture Capital, Private Equity, Merchant Banking and Media.
The Burrill family of venture capital funds has over $1 billion under
management and its merchant banking business is one of the industry leaders in
life sciences transactions. Burrill is also the creator, sponsor and
facilitator of over a dozen leading industry conferences worldwide and
publisher of a range of bio-intelligence reports including the Burrill Report,
which tracks the progress of the global biotechnology industry and annual
“State of the Industry” report. For more information, visit
http://www.burrillandco.com.
This press release contains
forward-looking statements within the meaning of the federal securities laws
concerning, among other things, the potential and prospects of Hollis-Eden
Pharmaceuticals, Inc. regaining and maintaining compliance with the listing
standards of the NASDAQ Global Market and its drug discovery program and its
drug candidates. Any statement included in this press release that are not a
description of historical facts are forward-looking statements that involve
risks, uncertainties, assumptions and other factors which, if they do not
materialize or prove correct, could cause Hollis-Eden's actual results to
differ materially from historical results or those expressed or implied by such
forward-looking statements. Such statements are subject to certain risks and
uncertainties inherent in the Company’s business, including, but not limited
to: the ability to complete preclinical and clinical trials successfully and
within specified timelines, if at all; the ability to obtain regulatory
approval for TRIOLEX® (HE3286), APOPTONE®
(HE3235) or any other investigational drug candidate; the Company's future
capital needs; the Company's ability to obtain additional funding; the ability
of the Company to protect its intellectual property rights and to not infringe
the intellectual property rights of others; the development of competitive
products by other companies; and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Except as
required by law, Hollis-Eden undertakes no obligation to update or revise the
information contained in this press release as a result of new information,
future events or circumstances arising after the date of this press release.
Source: Hollis-Eden Pharmaceuticals, Inc.
Contact:
Robert
Weber
CFO
Telephone: 858-587-9333
E-mail: rweber@holliseden.com
